Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

We are officially entering the era of cellular rejuvenation. A longevity startup just reached a major milestone by dosing its first human patient with a new therapy called ER-100.

The FDA recently gave the green light for these clinical trials. The primary goal right now is to see if we can actually reverse sight loss caused by aging.

This is not just about eyes. While vision is the first target, the underlying technology aims to reset the clock on cellular health.

If this works, the implications are massive. The company believes this same approach could eventually be used to treat a wide variety of age-related diseases.

Why this matters to you. For professionals in the AI and tech space, this signals a shift from treating symptoms to reprogramming biology.

As AI accelerates drug discovery and trial monitoring, these health projects are moving closer to reality. We are watching a convergence of biotech and software.

It is a reminder that the tools we build today might eventually help us live much longer and healthier lives.